Advanced: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.

ABC-01/ABC-02 (NCT00262769), ABC-03 (NCT00939848) IMPACT AND IMPLICATIONS: The data presented in this manuscript provide the benchmark outcome data for subgroups of ECCA and GBC treated with CisGem for future clinical trial design. Despite the absence of immunotherapy being involved, the lack of alternative comprehensive series highlights the value of this series. Future trials could involve novel targeted therapies or immunotherapy.